NOW AVAILABLE TO ORDER
IS THE TIME TO PREVENT INTRAOPERATIVE MIOSIS
AND REDUCE POSTOPERATIVE OCULAR PAIN
Omeros
®
and the Omeros logo
®
are registered trademarks, and Omidria
™
and the Omidria logo
™
are trademarks, of Omeros Corporation. © Omeros Corporation 2015, all rights reserved. 2015-096
Reference: 1. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2014.
UNIQUE HCPCS BILLING CODE: C9447
INDICATIONS AND USAGE
OMIDRIA is added to ophthalmic irrigation solution
used during cataract surgery or intraocular lens
replacement and is indicated for maintaining pupil
size by preventing intraoperative miosis and reducing
postoperative ocular pain.
IMPORTANT SAFETY INFORMATION
OMIDRIA must be added to irrigation solution prior
to intraocular use.
OMIDRIA is contraindicated in patients with a known
hypersensitivity to any of its ingredients.
Systemic exposure of phenylephrine may cause
elevations in blood pressure.
Use OMIDRIA with caution in individuals who have previously
exhibited sensitivities to acetylsalicylic acid, phenylacetic
acid derivatives, and other non-steroidal anti-infl ammatories
(NSAIDs), or have a past medical history of asthma.
The most commonly reported adverse reactions at
2-24% are eye irritation, posterior capsule opacifi cation,
increased intraocular pressure, and anterior chamber
infl ammation.
Use of OMIDRIA in children has not been established.
Please see the Full Prescribing Information for
OMIDRIA at www.omidria.com/prescribinginformation.
You are encouraged to report Suspected Adverse
Reactions to the FDA. Visit www.fda.gov/medwatch,
or call 1-800-FDA-1088.
OMIDRIA
™
(phenylephrine and ketorolac injection) 1% / 0.3% is
the fi rst and only FDA-approved treatment that both
1
:
Preemptively inhibits intraoperative miosis
Decreases postoperative ocular pain for 10 to 12 hours
